Design, Validate & Implement Robust Analytical Tools That Demonstrate Safety & Efficacy of Novel CRISPR-Based Therapeutics In Vivo & Ex Vivo

CRISPR-based therapies are undergoing a remarkable evolution, with drug developers striving to enhance the safety, precision and efficacy of their products. As this paradigm takes place, more complex CRISPR structures necessitate cutting-edge advancements in analytical methods and tools to effectively characterize the genome-edited products utilizing CRISPR technology.

As industry experts tread unchartered territory, the inaugural CRISPR-Based Therapy Analytical Development Summit has been convened, gathering more than 60 distinguished experts in analytical development devoted to the creation, refinements and implementation of more robust analytical tools specifically tailored to CRISPR-based constructs.

Within this intimate space, we will adopt a shared consensus and delve into a comprehensive array of analytical techniques central to any CRISPR-based toolkit. Topics of discussion will span pioneering technology that includes everything from novel methods to characterize the guide RNA and whole CRISPR complex, to the use of next-generation sequencing (NGS) to detect and assess off-targets for superior safety evaluations.

In response to the regulatory bodies’ insistence on high-quality data to substantiate the safety and efficacy of genome-edited products, this summit is imperative to all individual engaged in the development of analytical tools and methodologies utilizing CRISPR technology as we build for better guidance around CRISPR-edited products.

If your role centers around analytical expertise and gene edited specialization, this meeting will enable you to streamline your analytical development process and connect in a shared goal to deliver safer therapies, with superior therapeutic benefit to patients faster.

Your World-Class Speakers Include:

Howard Wu

Co-Founder & Chief Scientific Officer

Full Circles Therapeutics

Jessica Seitzer

Vice President - Genomic Operations

Intellia Therapeutics

Luca Pinello

Associate Professor

Massachusetts General Hospital & Harvard Medical School

Rachael Cohen

Head of Automation, Laboratory & Operations

Prime Medicine

TJ Cradick

Chief Scientific Officer

Excision Bio

Xi (CiCi) Shi photo

“I am really looking forward to the discussion at the meeting about the analytical methods, model development and regulatory suggestions on in vivo delivery, gene therapy using CRISPR technologies.”

- Xi Chi, Director at Takeda Pharmaceuticals

James Wang_Headshot

“There has never been a better time to discuss on analytical strategies and technologies specific for the development of gene edited cellular drug products.” 

- James Wang, Director at Bristol Myers Squibb



What to Expect:

18+ World-Class Expert Speakers  

60+ Attendees  

4 Hours of In-Person Networking  

2 Pre-Conference Workshops